Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
27 September 2023 - 10:00PM
Business Wire
– Company to host conference symposium to
discuss its approach to protecting dystrophic muscle featuring key
opinion leaders and 12-month results from the ARCH open label study
of EDG-5506 in adults with Becker –
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that the Company
will present on EDG-5506, an orally administered small molecule
designed to prevent contraction-induced muscle damage in
dystrophinopathies, at the 28th International Annual Congress of
the World Muscle Society (WMS). The conference will take place at
the Charleston Convention Center in Charleston, South Carolina,
from October 3-7, 2023.
Details of the Edgewise symposium and scientific posters at
WMS:
Edgewise Symposium with Key Opinion
Leaders
On Tuesday, October 3, 2023, at 4:30 pm ET, Edgewise will
sponsor a symposium, “Becker Muscular Dystrophy Natural History and
ARCH, an Open Label Study in Becker: Putting the Data in Context.”
The symposium will feature presentations by Edgewise leadership and
leading neuromuscular disease experts:
- Erik Niks, M.D., Ph.D., Neurologist, Leiden University Medical
Center
- Presentation: The Natural History of Becker Muscular
Dystrophy
- Sam Collins, M.D., Ph.D., Vice President of Clinical
Development, Edgewise Therapeutics
- Presentation: 12-Month Data from ARCH, an Open Label
Study in Becker Muscular Dystrophy
- Barry J. Byrne, M.D., Ph.D., Director, Powell Gene Therapy
Center, University of Florida
- Presentation: Putting the Data in Context
Only registered conference attendees can register for the
symposium.
Scientific Posters
Title: Characterization of short- and long-term proteomic
response to the fast skeletal myosin inhibitor, EDG-5506, in Becker
muscular dystrophy (P.254) Date: Friday, October 6, 2023,
2:00 – 3:00 pm ET
Title: Effects of EDG-5506, a fast myosin modulator, on
function and biomarkers of muscle damage in adults with Becker
muscular dystrophy (P.255) Date: Friday, October 6, 2023,
2:00 – 3:00 pm ET
Title: Development of a conceptual model of the patient
experience of Becker Muscular Dystrophy – a literature review and
qualitative interview study (P.256) Date: Friday, October 6,
2023, 2:00 – 3:00 pm ET
The full WMS Congress program is available here.
The Edgewise symposium presentation and posters will be
available on the Edgewise website when they are presented.
About EDG-5506 for Becker and Duchenne Muscular
Dystrophies
EDG-5506 is an orally administered small molecule designed to
prevent contraction-induced muscle damage in dystrophinopathies
including Duchenne and Becker. EDG-5506 presents a novel mechanism
of action designed to selectively limit the exaggerated muscle
damage caused by the absence or loss of functional dystrophin. By
minimizing the progressive muscle damage that leads to functional
impairment, EDG-5506 has the potential to benefit a broad range of
patients suffering from debilitating genetic neuromuscular
disorders. It is anticipated to be used as a single agent therapy,
but it may also provide an additional benefit in combination with
available therapies and therapies currently in development. In
August 2021, the U.S. Food and Drug Administration (FDA) granted
Fast Track designation to EDG-5506 for the treatment of individuals
with Becker.
The Company has completed a Phase 1 clinical trial of EDG-5506
designed to evaluate safety, tolerability, PK and pharmacodynamics
of EDG-5506 in adult healthy volunteers (Phase 1a) and in adults
with Becker (Phase 1b) (NCT04585464). In ARCH, an open-label,
single-center trial (NCT05160415) assessing long-term safety and
PK, decreases in biomarkers of muscle damage and trends toward
improvement in NSAA have been observed following 12 months of
treatment with EDG-5506. The Phase 2 trial of EDG-5506 in Becker
(CANYON) has been expanded to include an additional 120 adult
participants in a pivotal cohort called GRAND CANYON. CANYON is
fully enrolled; GRAND CANYON is currently enrolling. LYNX, an
ongoing Phase 2 trial (NCT05540860), is assessing safety, PK and
biomarkers of muscle damage in participants with Duchenne. The
Company is also continuing to recruit the DUNE Phase 2 exercise
challenge study, to evaluate the effect of EDG-5506 on biomarkers
of muscle damage following exercise in adults with LGMD2I, Becker
or McArdle disease at a single site in Denmark.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The company’s
deep expertise in muscle physiology is driving a new generation of
first-in-class therapeutics. EDG-5506 is an orally administered
skeletal myosin inhibitor in advanced clinical trials in patients
with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well
as McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a
novel cardiac sarcomere modulator for the treatment of HCM and
other disorders of cardiac diastolic dysfunction. The entire team
at Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X
(formerly Twitter), Facebook, Instagram and Threads.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference into this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927386586/en/
Investors & Media Michael Carruthers Chief Financial
Officer ir@edgewisetx.com
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From Apr 2024 to May 2024
Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
From May 2023 to May 2024